Trial Profile
A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor Paxalisib (GDC-0084) Administered to Patients With Glioblastoma Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Paxalisib (Primary)
- Indications Astrocytoma; Glioblastoma
- Focus Adverse reactions
- Sponsors Kazia Therapeutics
- 08 Mar 2023 Planned End Date changed from 30 Aug 2022 to 30 Mar 2023.
- 08 Mar 2023 Planned primary completion date changed from 30 Aug 2022 to 30 Mar 2023.
- 09 Nov 2022 According to a Kazia Therapeutics media release, final data from the study will be presented at the upcoming annual meeting of the Society for Neuro-Oncology (SNO).